Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios
Objectives: Onasemnogene Abeparvovec-xioi (AVXS-101) is a gene therapy intended for curative treatment of spinal muscular atrophy (SMA) with an expected price of around €2 000 000. The goal of this study is to perform a cost-effectiveness analysis of treatment of SMA I patients with AVXS-101 in The Netherlands including relapse scenarios. Methods: An individual-based state-transition model was used to model treatment effect and survival of SMA I patients treated with AVXS-101, nusinersen and best supportive care (BSC). The model included five health states: three health states according to SMA... Mehr ...
Verfasser: |
Broekhoff, Thomas F.
Sweegers, Carly C.G.
Krijkamp, Eline M.
Mantel-Teeuwisse, Aukje K.
Leufkens, Hubert G.M.
Goettsch, Wim G.
Vreman, Rick A. |
Dokumenttyp: |
Artikel |
Erscheinungsdatum: |
2021 |
Reihe/Periodikum: |
Broekhoff , T F , Sweegers , C C G , Krijkamp , E M , Mantel-Teeuwisse , A K , Leufkens , H G M , Goettsch , W G & Vreman , R A 2021 , ' Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios ' , Value in Health , vol. 24 , no. 6 , pp. 759-769 . https://doi.org/10.1016/j.jval.2020.09.021 |
Schlagwörter: |
/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
/ SDG 3 - Good Health and Well-being |
Sprache: |
Englisch |
Permalink: |
https://search.fid-benelux.de/Record/base-26842136 |
Datenquelle: |
BASE;
Originalkatalog |
Powered By: |
BASE |
Link(s) :
|
https://pure.eur.nl/en/publications/fb9e9c49-c0c0-4441-833d-4a83c2221cdb |